Bristlecone Advisors’s Biogen BIIB Stock Holding History

Bristlecone Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-721	Closed	-$205K	–	194
2020 Q3	$205K	Buy	+721	New	+$201K	0.04%	174

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bristlecone Advisors's BIIB Position: Q4 2020 in Review

Bristlecone Advisors sold out of Biogen (BIIB) in Q4 2020, closing a stake of 721 shares — an estimated $205K sold.

Bristlecone Advisors first reported a position in BIIB in Q3 2020 and held it in 1 quarter. The position peaked at $205K in Q3 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Bristlecone Advisors reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Bristlecone Advisors sold 721 Biogen shares in Q4 2020, an estimated $205K.
Bristlecone Advisors first reported a position in Biogen in Q3 2020 and held it in 1 quarter.
Bristlecone Advisors's Biogen position peaked at $205K in Q3 2020.
1,060 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Bristlecone Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.